BioSpace News Archive

Drug Development

Biotech Company Takes a Hit After Axing HBV Therapy over Safety Concerns

Shares of Assembly Biosciences have fallen more than 20% in premarket trading after the company discontinued the development of a hepatitis B therapeutic candidate.

September 2, 2021
·
2 min read
·
Alex Keown
Career Advice

3 Ways to Encourage Positive Mental Health at Work

The pandemic and its subsequent effect on the workplace has been the source of stress for many professionals. Here are 3 ways to boost mental health at work.

September 2, 2021
·
4 min read
·
Porschia Parker-Griffin
Job Trends

Texas Plants its Flag as Next US Biotech Hub

BioLabs is opening its next hub in Dallas in a 37,000-square-foot flexible life science facility. The Biotech+ Hub can accommodate 35 startups, for which it’s now accepting applications.

September 2, 2021
·
3 min read
·
Kate Goodwin
Policy

FDA Crackdown on JAK Drug Class Unwelcome News for Pharma Giants

Henceforth, all JAK-inhibiting drugs like AbbVie’s Rinvoq, Pfizer’s Xeljanz, and Lilly’s Olumiant, have been ordered to include a warning label on the medicine to be sold in the U.S.

September 2, 2021
·
4 min read
·
BioSpace Editorial Staff
Deals

Judge Releases Sacklers from Future Opioid Lawsuits, Approves Purdue Settlement

The Sacklers did not admit to any wrongdoing and have never been charged directly for the issue. Still, Purdue Pharma has pleaded guilty twice in its erroneous marketing efforts for OxyContin.

September 2, 2021
·
2 min read
·
Vanessa Doctor, RN
Business

BioSpace Movers & Shakers: Sept. 3

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

September 2, 2021
·
7 min read
·
Alex Keown
Genetown

Biogen Giving Out Free Doses of Alzheimer’s Drug Aduhelm

The company sent the medication to a Florida neurology clinic free of charge.

September 2, 2021
·
3 min read
·
Mark Terry
Business

Meet the World’s Top Life Sciences Billionaires

The life sciences industry was well-represented, with a handful of names featured in the top 100.

September 2, 2021
·
2 min read
·
Ellen Bombela
Drug Development

Takeda Blood Cancer Drug Fails in Phase III

Takeda said that Phase III PANTHER, which studied the effectiveness of pevonedistat for different types of leukemia, did not produce significant results in terms of event-free survival.

September 2, 2021
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Vaccines Cut “Long-Haul” COVID Risk in Half, While Kids Test Positive in Droves

A study published in The Lancet Infectious Diseases found that the Pfizer-BioNTech, Oxford-AstraZeneca or Moderna vaccines resulted in a drop in “long-haul” COVID-19 by 50%.

September 2, 2021
·
3 min read
·
Mark Terry